title: Potent inhibitory activity of chimeric oligonucleotides targeting two different sites of human telomerase.
abstract: Suppression of telomerase activity in tumor cells has been considered as a new anticancer strategy. Here, we present chimeric oligonucleotides (chimeric ODNs) as a new type of telomerase inhibitor that contains differently modified oligomers to address two different sites of telomerase: the RNA template and a suggested protein motif. We have shown previously that phosphorothioate-modified oligonucleotides (PS ODNs) interact in a length-dependent rather than in a sequence-dependent manner, presumably with the protein part of the primer-binding site of telomerase, causing strong inhibition of telomerase. In the present study, we demonstrate that extensions of these PS ODNs at their 3'-ends with an antisense oligomer partial sequence covering 11 bases of the RNA template cause significantly increased inhibitory activity, with IC(50) values between 0.60 and 0.95 nM in a Telomeric Repeat Amplification Protocol (TRAP) assay based on U-87 cell lysates. The enhanced inhibitory activity is observed regardless of whether the antisense part is modified (phosphodiester, PO; 2'-O-methylribosyl, 2'-OMe/PO; phosphoramidate, PAM). However, inside intact U-87 cells, these modifications of the antisense part proved to be essential for efficient telomerase inhibition 20 hours after transfection. In particular, the chimeric ODNs containing PAM or 2'-OMe/PO modifications, when complexed with lipofectin, were most efficient telomerase inhibitors (ID(50) = 0.04 and 0.06 microM, respectively). In conclusion, ODNs of this new type emerged as powerful inhibitors of human telomerase and are, therefore, promising candidates for further investigations of the anticancer strategy of telomerase inhibition.
authors.affiliation: Max-Delbrück-Centrum für Molekulare Medizin, D-13125 Berlin, Germany. emat@mdc-berlin.de
authors.forename: Eckart
authors.initials: E
authors.lastname: Matthes
authors.forename: Christine
authors.initials: C
authors.lastname: Lehmann
authors.forename: Marianne
authors.initials: M
authors.lastname: Stulich
authors.forename: Yong
authors.initials: Y
authors.lastname: Wu
authors.forename: Lora
authors.initials: L
authors.lastname: Dimitrova
authors.forename: Eugen
authors.initials: E
authors.lastname: Uhlmann
authors.forename: Martin Von
authors.initials: MV
authors.lastname: Janta-Lipinski
mesh_terms: D001483:Base Sequence; D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D000071228:Polyelectrolytes; D011108:Polymers; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D000071228:Polyelectrolytes; D011108:Polymers; D019098:Telomerase